Drug conversion efficiency: Johnson & Johnson ranked first in PII index for three consecutive years

Source: Biovalley 2015-3-18 has always been a simple way to measure the strength of a biomedical company by its turnover, number of new drugs, etc However, how to better measure the innovation of a biomedical company? If there is a drug molecule to be developed in hand, which company can give it to maximize the benefits of this drug? Idea's annual production innovation index (PII) may tell you the answer This list has been published for five years, and has attracted wide attention in the biomedical industry As the biomedical industry has changed in the past year, the top ten "martial arts experts" on this list have changed a lot Johnson & Johnson has been at the top of the list for three consecutive years Johnson & Johnson is famous for its high efficiency in drug development in the biomedical industry This year is also the third year for Johnson & Johnson to remain at the top of the PII list The company is involved in a variety of diseases, and its annual sales of eight drugs have exceeded double-digit growth in the past year, reaching as much as 14.9% The sales volume of olysio / sovriad hepatitis C combination therapy developed by the company has reached as much as US $2 billion in the past 12 months! In addition, the new drugs developed by the company, such as invokana, imbruvica, zytiga, invega, sustenna and rezolsta, have been approved in succession, which further strengthens its position as the "leader of Wulin" Sovaldi is in the hand I have Geely de in the world In recent years, Geely de has become the most famous company in the world Sovaldi, a new hepatitis C therapy developed by the company, has rapidly swept the world pharmaceutical market with its amazing efficacy In just one year, the sales volume of this drug has reached as much as US $10 billion which is eye-catching! It can be said that sovaldi is in hand, and I have it all over the world In this year's PII index, Geely is the most eye-catching company Gilead jumped from 18th place to 2nd place last year, and its achievements in the field of hepatitis C treatment are indispensable In 2014, the company launched harvoni, a new hepatitis C therapy Zybelig, a new leukemic drug developed by zybelig, has also obtained FDA's breakthrough treatment certification and market approval In addition, truvada, which is in the research and development stage, has made good progress No wonder Novartis, last year's second place pharmaceutical giant, is willing to be defeated by such blooming achievements The strength of Novartis is still not to be underestimated Although Novartis ranked third in PII this year, its overall R & D strength for new drugs is still very strong The company's current best-selling drug system includes afinitor, Tasigna, zortress and gilenya At the same time, the company still won a series of important achievements in 2014 Among them, zykadia, cosentix and xolair, which are used to treat metastatic lung cancer, have been approved by FDA In addition, bexsero developed by the company has been highly valued by FDA and awarded breakthrough drug certification All these prove that Novartis is still one of the most powerful biomedical giants in drug transformation However, the company's failure to apply for heart disease drug serelaxin and Tasigna's EMA application this year is believed to be the main reason for the decline In addition to the three pharmaceutical companies mentioned above, Baijian Aidi, Amgen and celgene have all entered the top ten, with the same impressive performance Among them, celgene jumped to No 8 from No 16 last year, making remarkable progress The productive innovation index (PII) measures the comprehensive strength of a biopharmaceutical company in drug development, drug commercialization and drug R & D innovation ability by comprehensively considering drug sales, new drug approval speed, clinical research loss rate (especially clinical phase III Research) and other indicators The list was released by idea Pharma, a famous company, in its fifth year It has a high reference value in the biomedical industry.